GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

Dostarlimab (Jemperli, GlaxoSmithKline) is indicated 'in combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Dostarlimab (Jemperli) with platinum-based chemotherapy is available on the NHS. It is a possible treatment for when systemic treatment is suitable in adults with primary endometrial cancer that has ...

Glaxosmithkline Pharmaceutical advanced 3.21% to Rs 2,879.70 after the company's standalone net profit jumped 34.73% to Rs 260.14 crore on a 6.06% increase in revenue from operations to Rs 966.08 ...

GlaxoSmithKline Pharmaceuticals Ltd. reported a 36% increase in consolidated net profit to Rs 263 crore for the quarter ended ...

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

People with the following cancer types responded well: Rectal Urothelial Hepatobiliary Colon Gastric Esophagogastric junction tumors also had some response. In this trial, endometrial, prostate ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE: GSK) stands against other best ...

Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last decades, with most active ...